APPLICATIONS PUBLISHED 17 SEPTEMBER 2003
Published: 1-Feb-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Microsystem for controlled dispensation of an active substance from a reservoir
Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung 1343471*
Thixotropic nasal spray
Impetus 1343472*
Pharmaceutical dronedarone compsn for parenteral administration
Sanofi-Synthelabo 1343473*
Intraocular irrigating solution having improved flow characteristics
Alcon 1343474*
Self-forming, thermodynamically stable liposomes and their applications
Biozone Laboratories 1343475*
Preparation of large liposomes by infusion into PEG
Biomira 1343476*
Treatment of interoperable tumours by stereotactic injection of microspheres
Ethypharm 1343477*
Induced phase transition method for the production of microparticles containing hydrophilic active agents
Nektar Therapeutics 1343478*
Aerogel powder therapeutic agents
Aspen Aerogels 1343479*
Induced phase transition method for the production of microparticles containing hydrophobic active agents
Nektar Therapeutics 1343480*
Process for the preparation of a fast-dissolving dosage form
Ranbaxy Laboratories 1343481*
Prolamin-based sustained-release compsns and delayed-onset compsns
Labopharm 1343482*
Transdermal system containing a novel high potency progestagen
Schering 1343483*
Transdermal systems (TDS) that contain inhibitors of phosphodiesterase IV
Guenther, Clemens 1343484*
Lipid-based nitric oxide donors
Scimed Life Systems 1343485*
Pharmaceutical or cosmetic compsns and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration
Laboratories Expanscience 1343486*
Methods and compsns to treat conditions associated with neovascularisation
Wackvom 1343487*
Treatment of statin side effects
Centre for Molecular Biology and Medicine 1343488*
Sterile bicarbonate-free dialysis concentrate solutions
Dialysis Solutions 1343489*
Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof
Degussa 1343490*
Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
Merck Sante; Institut National de la Sante et de la Recherche Medicale (INSERM) 1343491*
Treatment of mucositis
Rxkinetix 1343492*
Use of (-)-(3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
Metabolex 1343493*
Tetrapartate prodrugs
Enzon 1343494*
Methods of treating anxiety disorders
Wyeth 1343495*
Anticancer agent comprising mycolactone
Biogenia 1343496*
d-2, -1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and anti-ischaemic agents, useful in the treatment of cerebral ischaemia resulting from stroke
K and K Biosciences 1343497*
Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
Warner-Lambert; Lucas, Brian Ronald 1343498*
Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
Bristol-Myers Squibb 1343499*
Compsns comprising temozolomide and thalidomide and methods for the treatment of cancer
Memorial Sloan-Kettering Cancer Centre 1343500*
Therapy for herpes neurological viral conditions utilising 1,4-dihydropyridine calcium channel blockers
Zik, Howard 1343501*
Methods of inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
Idenix (Cayman); Universita' degli Studi di Cagliari 1343502*
Heteroaryl urea neuropeptide Y Y5 receptor antagonists
Schering 1343503*
Pharmaceutical formulation of gepirone for oral administration
Akzo Nobel 1343504*
CXCR3 antagonists
Tularik 1343505*
Pharmaceutical formulation containing pyrazolo 4,3-D]pyrimidines and antithrombitic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
Merck 1343506*
Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs
Virocell 1343507*
Use of an oestrogen in the manufacture of a compsn containing oestrogen for the treatment of atrophic vaginitis
Kvorning, Ingelise 1343508*
Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
Endeavour Pharmaceuticals 1343509*
Light stabilised antimicrobial materials
Bristol-Myers Squibb 1343510*
Shark meat extract
Industrial Research 1343511*
Injectable solution with anti-inflammatory effect and process for manufacturing the same
Immunomod 1343512*
Compsns containing an active fraction isolated from Scutelllariae Barbatea and methods of use
Wackvom 1343513*
Chlamydia PMP proteins, gene sequences and uses thereof
Antex Biologicals 1343514*
Compounds for sustained release of orally delivered drugs
Xenoport 1343515*
Analogues of thiocoraline and BE-22179
The Scripps Research Institute 1343516*
Survical promoting NCM binding and NCAM ligand binding compsns
Enkam Pharmaceuticals 1343517*
Stabilised interferon compsns
Chiron 1343518*
Modulation of SMR1-NEP interactions in CNS disorders giving rise to mental disorders
Institut Pasteur; Centre National de la Recherche Scientifique 1343519*
New therapeutic use of SMR1 peptides
Institut Pasteur; Centre National de la Recherche Scientifique 1343520*
Method for the stabilising biomolecules (e.g. insulin) in liquid formulations
Battelle Memorial Institute 1343521*
Procollagen (III) propeptides and related substances for treating fibrotic diseases
Burchardt, Elmar 1343522*
Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
Boehringer Ingelheim Pharma 1343523*
Vaccine based on a cellular penetration factor from an apicomplexan parasite
University College London 1343524*
Improved Mycoplasma hyopneumoniae bacterin vaccine
Wyeth 1343525*
Vaccine
SmithKline Beecham 1343526*
Adjuvant compsn formulations
American Cyanamid 1343527*
Methods for stimulating nervous system regeneration and repair by inhibition of phosphodiesterase type 4
Research Foundation of the City University of New York 1343528*
NSAID formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
The Board of Regents, The University of Texas System 1343529*
Oral pharmaceutical compsn containing a block copolymer
AstraZeneca 1343530*
Conjugates of antibodies and anticancer drugs
McGill University 1343531*
Lentiviral vector-mediated gene transfer and uses thereof
Research Development Foundation 1343532*
Device for synthesis of radiopharmaceutical products
Ion Beam Applications 1343533*
Treatment of cancer with positron-emitting radiopharmaceuticals
Yeung, Alex Wah Hin 1343534*
Oxidation of dangerous chemical and biological substances
Atlantium Lasers 1343535*
Method of decellularising foreign material for the production of bioprostheses
Auto Tissue 1343536*
